{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Biotech Intuition","title":"Biotech Daily Top Stories - October 21, 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/c9b3ae3d\"></iframe>","width":"100%","height":180,"duration":529,"description":"Daily - Oct 21, 2026 - Show Notes\nGet personalized biotech intelligence and catalyst tracking from SOZO Intuition:\nhttps://sozointuition.com\nCHAPTERS\n00:00 SOZO Biotech Daily Brief\n00:35 Fenebrutinib Cuts Relapse Rate in Multiple Sclerosis\n01:11 Fenebrutinib Slows Chronic Brain Lesion Progression\n01:46 Genentech Highlights Pediatric Ocrevus and Enspryng\n02:23 Miv-cel Shows 1-Year Mobility Gains in Stiff Person\n03:00 Miv-cel Enables Immunotherapy Freedom at One Year\n03:38 Oral Olorofim Meets Non-Inferiority in Aspergillosis\n04:12 Olorofim Reduces Renal Injury; Resubmission Planned\n04:48 FDA Approves ORLADEYO Oral Pellets for HAE\n05:30 LMN-201 Biologic Cocktail Succeeds in Phase 2 C. diff\n06:13 BIOX-101 Reduces Edema Growth in Brain Hemorrhage\n06:56 Servier Partners with Okomera on Tumor Miniaturization\n07:37 Looking ahead\n08:24 SOZO Intuition\nSUMMARY\nSOURCES BY CHAPTER\nSOZO BIOTECH DAILY BRIEF\nFENEBRUTINIB CUTS RELAPSE RATE IN MULTIPLE SCLEROSIS\nGenentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 2026-10-21:\nhttps://www.gene.com/media/press-releases/15139/2026-10-21/genentech-presents-new-pivotal-trial-data-across-broad-neuroimmunology-portfolio-at-mstoronto2026\nFENEBRUTINIB SLOWS CHRONIC BRAIN LESION PROGRESSION\nGENENTECH HIGHLIGHTS PEDIATRIC OCREVUS AND ENSPRYNG\nMIV-CEL SHOWS 1-YEAR MOBILITY GAINS IN STIFF PERSON\nKyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto…:\nhttps://www.globenewswire.com/news-release/2026/10/21/3385400/0/en/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-clinical-benefit-of-miv-cel-in-stiff-person-syndrome-at-ms-toronto.html\nQuell Therapeutics Advances QEL-005 to Second Dose Cohort in CHILL Phase 1/2 Trial in Rheumatoid Arthritis and Systemic Sclerosis 2026-10-21:...","thumbnail_url":"https://img.transistorcdn.com/9CRjd85JHtM1TuR9eJILKciqKkE8Zi-g-0T-xOirVCU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZGRl/OGVlNDg2NjQ1MmUx/OTMyMjcxZmY3Zjdk/N2JiYS5qcGVn.webp","thumbnail_width":300,"thumbnail_height":300}